The Impact of Cryopreservation on Hematopoietic Stem Cell Engraftment and Post-transplant Outcome During the COVID-19 Pandemic

Overview

Journal In Vivo

Specialty Oncology

Date 2024 Apr 30

PMID 38688614

Authors

Anna Strzelec

Natalia Gawlik-Rzemieniewska

Anna Klima

Karolina Panek

Grzegorz Helbig

Affiliations

Soon will be listed here.

Abstract

Background/aim: The COVID-19 pandemic has had a significant impact on the current management of allotransplanted patients in whom fresh hematopoietic stem cells (HSCs) were replaced by cryopreserved ones. The aim of the study was to determine the efficacy and safety of cryopreserved HSCs when compared with the fresh ones.

Patients And Methods: A retrospective analysis of 254 allogeneic stem cell transplantations (HSCT) procedures performed between 2020-2021 included the following donors: matched related (MRD; n=68), matched unrelated (MUD; n=148) and haploidentical (HID; n=38). 50% of patients (non-cryo group) received fresh grafts, whereas the remaining patients (cryo group) were transplanted with cryopreserved cells.

Results: No differences in terms of median days to neutrophil [MRD/MUD/HID cryo- and non-cryo groups: 17 vs. 16 (p=0.27), 19 vs. 18 (p=0.83), 22 vs. 22 (p=0.83) days, respectively] and platelet [MRD/MUD/HID cryo- and non-cryo groups: 14 vs. 14 (p=0.25), 17 vs. 17 (p=0.33), 21 vs. 19 (p=0.36) days, respectively] engraftments were demonstrated. Among MUD graft recipients, platelet engraftment rates were 81% in the cryo- and 96% in the non-cryo group (p=0.01). OS rates were comparable at 1 year after HSCT between MRD/MUD/HID cryo- and non-cryo groups: 53% vs. 60% (p=0.54), 60% vs. 66% (p=0.5), 50% vs. 41% (p=0.56), respectively.

Conclusion: During the COVID-19 pandemic, cryopreserved HSCs did not have a negative impact on median engraftment time and OS when compared to fresh HSCs. In the MUD group, platelet engraftment rate was lower in cryopreserved HSC recipients.

References

Purtill D, Hutchins C, Kennedy G, McClean A, Fraser C, Shaw P . Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transplant Cell Ther. 2021; 27(12):1022.e1-1022.e6. PMC: 10202757. DOI: 10.1016/j.jtct.2021.09.012. View

Mitrus I, Smagur A, Fidyk W, Czech M, Prokop M, Chwieduk A . Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study. Bone Marrow Transplant. 2017; 53(3):274-280. DOI: 10.1038/s41409-017-0056-6. View

Rimando J, Slade M, Dipersio J, Westervelt P, Gao F, Liu C . HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Adv. 2018; 2(24):3590-3601. PMC: 6306877. DOI: 10.1182/bloodadvances.2018025437. View

Whaley D, Damyar K, Witek R, Mendoza A, Alexander M, Lakey J . Cryopreservation: An Overview of Principles and Cell-Specific Considerations. Cell Transplant. 2021; 30:963689721999617. PMC: 7995302. DOI: 10.1177/0963689721999617. View

Pomeroy K, Comizzoli P, Rushing J, Lersten I, Nel-Themaat L . The ART of cryopreservation and its changing landscape. Fertil Steril. 2022; 117(3):469-476. DOI: 10.1016/j.fertnstert.2022.01.018. View

Ciurea S, Cao K, Fernandez-Vina M, Kongtim P, Al Malki M, Fuchs E . The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018; 53(5):521-534. PMC: 7232774. DOI: 10.1038/s41409-017-0062-8. View

Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M . Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program. Transplant Cell Ther. 2021; 27(8):664.e1-664.e6. PMC: 8098035. DOI: 10.1016/j.jtct.2021.04.022. View

Biernacki M, Sheth V, Bleakley M . T cell optimization for graft-versus-leukemia responses. JCI Insight. 2020; 5(9). PMC: 7253012. DOI: 10.1172/jci.insight.134939. View

Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F . Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2020; 56(3):532-535. PMC: 7289070. DOI: 10.1038/s41409-020-0970-x. View

10.

Montoro J, Boumendil A, Finel H, Bramanti S, Castagna L, Blaise D . Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society.... Transplant Cell Ther. 2023; 30(2):210.e1-210.e14. DOI: 10.1016/j.jtct.2023.11.021. View

11.

Worel N, Ljungman P, Verheggen I, Hoogenboom J, Knelange N, Eikema D . Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working.... Bone Marrow Transplant. 2023; 58(12):1348-1356. DOI: 10.1038/s41409-023-02099-w. View

12.

Cottle C, Porter A, Lipat A, Turner-Lyles C, Nguyen J, Moll G . Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics. Curr Stem Cell Rep. 2022; 8(2):72-92. PMC: 9045030. DOI: 10.1007/s40778-022-00212-1. View

13.

Bittencourt M, Mariano L, Moreira F, Schmidt-Filho J, Mendrone-Jr A, Rocha V . Cryopreserved versus non-cryopreserved peripheral blood stem cells for autologous transplantation after high-dose Melphalan in multiple myeloma: comparative analysis. Bone Marrow Transplant. 2018; 54(1):138-141. DOI: 10.1038/s41409-018-0250-1. View

14.

Madsen B, Hilscher M, Zetner D, Rosenberg J . Adverse reactions of dimethyl sulfoxide in humans: a systematic review. F1000Res. 2019; 7:1746. PMC: 6707402. DOI: 10.12688/f1000research.16642.2. View

15.

Maurer K, Kim H, Kuczmarski T, Garrity H, Weber A, Reynolds C . Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021; 5(23):5140-5149. PMC: 9153034. DOI: 10.1182/bloodadvances.2021005139. View

16.

Welschinger L, Milton C, Zaunders G, Ashraf A . Effect of nucleated cell count and cryopreservation on engraftment post autologous stem cell transplant. Transfus Apher Sci. 2022; 61(6):103495. DOI: 10.1016/j.transci.2022.103495. View

17.

Yang M, Xin L, Li H, Lu X, Pan X, Lei S . Risk factors for bloodstream infection in paediatric haematopoietic stem cell transplantation: a systematic review and meta-analysis. J Hosp Infect. 2023; 139:11-22. DOI: 10.1016/j.jhin.2023.06.003. View

18.

Ersal T, Ozkocaman V, Yalcin C, Orhan B, Candar O, Cubukcu S . The effect of cryopreservation on engraftment kinetics in fully matched allogeneic stem cell transplantation: Real-life data and literature review. Transfus Apher Sci. 2023; 62(6):103821. DOI: 10.1016/j.transci.2023.103821. View

19.

Berens C, Heine A, Muller J, Held S, Mayer K, Brossart P . Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. Cytotherapy. 2016; 18(10):1325-31. DOI: 10.1016/j.jcyt.2016.06.014. View

20.

Gupta A, Meena J, Haldar P, Tanwar P, Seth R . Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res. 2021; 11(5):544-563. PMC: 8610798. View